OncLive’s Post

A breakthrough in triple-negative breast cancer (TNBC). A preclinical study reveals promising results for a new selective CDK9 inhibitor, CDDD11-8, in targeting transcription in TNBC. In vitro and in vivo models demonstrate inhibition of proliferation, induction of cell cycle arrest, and increased apoptosis across TNBC subtypes. Importantly, CDDD11-8 shows efficacy in patient-derived organoids and explants, with minimal toxicity to normal tissues. These findings highlight CDK9 as a viable therapeutic target and suggest CDDD11-8 as a potential treatment option for TNBC patients. #BreastCancerResearch #TNBC #CDK9Inhibitor #PrecisionMedicine https://lnkd.in/gkkydnuF

⭐It's been amazing to see the recent results of a Phase 2 clinical trial conducted on ARX517, a novel anti-androgen therapy for metastatic castration-resistant prostate cancer (mCRPC). The results suggest ARX517 is safe and tolerable at all tested doses, with encouraging clinical outcomes ✅🔬 Treatment-resistant prostate cancer is a terrible illness that can cause debilitating symptoms. We are encouraged by the promise shown by ARX517 and the possibility of a new hope for those affected by this condition 💪🙌 #ARX517 #MetastaticProstateCancer #MCRPC #Oncology #ClinicalTrials #ClinicalResearch #Biotechnology #LifeScience #InnovationalMedicine #ElixirAssociates #StaffingPartner

FDA Approves First One-time Cell Therapy for a Solid Tumor! Exciting strides in immunotherapy! The FDA's impending approval decision for Iovance Biotherapeutics has the potential to breathe new life into the field, which has been evolving for over four decades. This milestone exemplifies the relentless pursuit of progress in healthcare, where groundbreaking advancements often arise from years of dedicated research and development. If approved, Iovance's treatment could offer a promising new option for patients with certain types of cancer, providing a beacon of hope in the ongoing fight against the disease. This news underscores the profound impact that innovative therapies can have on improving patient outcomes and transforming the landscape of cancer care. #Immunotherapy #HealthcareInnovation #FDAApproval #CancerTreatment https://lnkd.in/eV6CXvPK

#cancerresearch #oncology #metabolism #cancertreatment #melanoma https://lnkd.in/gm8yK_Kx Combo treatment targets melanoma Researchers have worked out why #melanoma is resistant to targeted therapies, such as those that block the protein BRAF. When treated with a BRAF inhibitor (BRAFi), mice with melanoma burned more #fatty #acids, which led to the animals becoming resistant to the therapy over time. A heart-disease drug approved in the United States and Europe, ranolazine, slowed the comeback of tumours that had become resistant. Further data suggested that ranolazine made BRAFi-resistant tumours more vulnerable to immunotherapy. The data provide “the scientific rationale to combine ranolazine with BRAFi to delay the onset of acquired resistance”, the researchers write.

Patient-derived organoids are 3D cell models created in a lab and useful for drug screening and testing. Recently, tumor organoids from patients with colorectal cancer have shown high predictability for treatment outcomes during preclinical testing. These findings were published in Cell Reports Medicine (DOI: 10.1016/j.xcrm.2023.101335). However, growing and maintaining organoids are still challenging and require adjusting and optimizing the conditions. #organoids #drugscreening #preclinicaltesting

New blog alert! 🚨 Learn all about the application of syngeneic models in immunotherapy preclinical drug development and how they can provide valuable insights into the immune landscape of tumors. Dive into the latest research and discover how these models are revolutionizing the way we approach cancer treatment. Don't miss out on this informative read! 🧬🔬👩🔬 https://hubs.ly/Q02D8l7b0 #Immunotherapy #DrugDevelopment #SyngeneicModels #CancerResearch

I am excited to share this paper, I worked on with Rachna Shroff, MD, FASCO, and published in Future Oncology (Taylor & Francis Group) which demonstrates recent developments in the fight against biliary tract cancer (BTC). A few key points: BTC's molecular heterogeneity offers new hope with potentially targetable genetic alterations. While first-line treatments remain chemotherapy-based, ongoing clinical trials exploring immunochemotherapy regimens and FGFR2 inhibitors may soon change this landscape. Promisingly, MDM2–p53 antagonists like brigimadlin are showing durable responses in clinical trials, marking a significant step forward for BTC patients. Molecular testing is essential and strongly recommended in treatment guidelines for BTC, paving the way for more personalized and effective therapies. #CancerResearch #BiliaryTractCancer #Oncology #MedicalInnovation #ClinicalTrials #curecca #HopeInResearch

Identification of collagen subtypes of gastric cancer for distinguishing patient prognosis and therapeutic response 📢 #Innovation #Oncology #Cancer

Let's start 2024 with a blast! Our latest publications Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? has just been published in cells. We discuss the current state of allogeneic CAR-T cell therapy with regards to the different ways allogeneic CAR-Ts can be made (different sources, different processess) and what are the current clinical results (oncology for the moment) actually showing? We also discuss the challenges and the current ways by which these challenges can be conquered. You can read all about it here: https://lnkd.in/e_d6bvVn

Though CAR T-cell therapy has seen promising results in oncology, there are many types of cancers that are not yet eligible for this treatment. This is not the only unmet need in this area, however, as 70% of CAR T-cell therapy patients are at risk of Cytokine Release Syndrome (CRS) as a side effect of their treatment.    CytoAgents’ drug candidate, CTO1681, is a powerful solution to CRS. It reduces the cytokines generated during CRS in CAR T-cell therapy while enabling the body to maintain appropriate cytokine levels. Learn about CytoAgents and our mission to treat CRS here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh